Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
NEW HAVEN, Conn. and TOKYO, Oct. 3 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that it has entered into an agreement with Sankyo, Co., Ltd...
NEW HAVEN, Conn. and TOKYO, Sept. 21 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that it has entered into a pharmacogenomic research collaboration...
NEW HAVEN, Conn., and MARSEILLE, France, Sept. 12 /PRNewswire-FirstCall/ -- Privately-held Ipsogen SAS and Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) announced today that they have signed...
- Increases Presence in EU Ag Genotyping Market - NEW HAVEN, Conn., Aug. 23 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) announced today that it will provide its...
- Will Address EU Mandate for Sheep-Breeding Programs That Confer Resistance to Scrapie - NEW HAVEN, Conn., Aug. 11 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC...
Genaissance Pharmaceuticals Enters into HAP(TM) Technology License Agreement with Organon NEW HAVEN, Conn. and OSS, Netherlands, July 18 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals...
Clinical Data to Acquire Genaissance Pharmaceuticals Combined Company to Deliver Industry-Defining Theranostics NEWTON, Mass., and NEW HAVEN, Conn., June 21 /PRNewswire-FirstCall/ -- Clinical...
Clinical Data, Inc. (NASDAQ:CLDA) and Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that they have signed an agreement for Clinical Data to acquire Genaissance Pharmaceuticals in...
Genaissance to Provide Pharmacogenetic Support to INC Research, Its First CRO Partner NEW HAVEN, Conn., June 7 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) announced...
Genaissance Reports First Quarter 2005 Results Company Cites Progress In Key Areas, Including Recent Increase In Cash Reserves NEW HAVEN, Conn., May 3 /PRNewswire-FirstCall/ -- Genaissance...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
